Francesca Longhin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Francesca Longhin has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Barbara Di Camillo
Department of Information Engineering, University of Padua, Padua, Italy
3 shared publications - Alessandro Guazzo
University of Padova
1 shared publication - Annamaria Cattelan
Infectious and Tropical Diseases Unit, Padua University Hospital, 35128 Padua, Italy
1 shared publication - Claudia Del Vecchio
Department of Molecular Medicine, University of Padua, Padua, Italy
1 shared publication - Claudio Salaris
Department of Molecular Medicine, University of Padova, Padova, Italy
1 shared publication - Diego Boscarino
AB ANALITICA, Srl, Padua, Italy
1 shared publication
Latest Publications
- Open Access
- 27 November 2025
- Published by Springer Nature in BMC Bioinformatics
- Vol. 26 (1) , 287
MOV&RSim: computational modelling of cancer-specific variants and sequencing reads characteristics for realistic tumoral sample simulation
Background: Bioinformatics pipelines for variant calling have undergone significant advancements due to the decreasing costs of next-generation sequencing. Accurate mutation detection is crucial for personalised medicine in cancer, particularly in assignment of therapy. Somatic variant calling, however, remains challenging due to diverse cancer types, heterogeneity, complex mutational profiles, and unpredictable sequencing errors. A dataset of fully characterised tumoral genomes and sequencing reads, large enough to represent the variability inherent in different cancer types, is still lacking, even considering synthetic data. The lack of such datasets hampers rigorous evaluation, benchmarking and optimization of variant callers for specific cancer types. Results: The contribution of this work is twofold. First, we conducted a comprehensive analysis of nine somatic sample simulators (Synggen, BAMSurgeon, SVEngine, VarSim, Xome-Blender, tHapMix, Pysim-sv, SCNVSim, HeteroGenesis) assessing their ability to control biological parameters , including variants characteristics (type, number, position, length, content, zygosity), and sample characteristics (clonality, contamination); and technical parameters , including reads characteristics (sequencing errors, coverage, base qualities). No single simulator provided complete control over both biological and technical parameters, nor guidance on tuning biological parameters for cancer-specific simulations. Consequently, we developed MOV&RSim, a novel simulator that leverages data-driven information to set variants and reads characteristics, producing realistic tumoral samples, and providing full control on biological and technical parameters. Additionally, we leveraged well-annotated variant databases to create cancer-specific presets that inform the simulator’s parameters for 21 cancer types. Conclusion: This new simulator, containerised with Docker and freely available for academic use, empowers users to define each biological parameter of a tumoral genome and faithfully replicates the variability of technical noise observed in real sequencing reads. The proposed simulator and presets represent the most adaptable and comprehensive framework currently available for generating tumor samples, enabling comprehensive benchmarking and, ultimately, the optimization of somatic variant callers across diverse cancer types.
- 27 November 2025
- Published by Springer Nature in BMC Bioinformatics
- Vol. 26 (1) , 287
Open AccessMOV&RSim: computational modelling of cancer-specific variants and sequencing reads characteristics for realistic tumoral sample simulation
Background: Bioinformatics pipelines for variant calling have undergone significant advancements due to the decreasing costs of next-generation sequencing. Accurate mutation detection is crucial for personalised medicine in cancer, particularly in assignment of therapy. Somatic variant calling, however, remains challenging due to diverse cancer types, heterogeneity, complex mutational profiles, and unpredictable sequencing errors. A dataset of fully characterised tumoral genomes and sequencing reads, large enough to represent the variability inherent in different cancer types, is still lacking, even considering synthetic data. The lack of such datasets hampers rigorous evaluation, benchmarking and optimization of variant callers for specific cancer types. Results: The contribution of this work is twofold. First, we conducted a comprehensive analysis of nine somatic sample simulators (Synggen, BAMSurgeon, SVEngine, VarSim, Xome-Blender, tHapMix, Pysim-sv, SCNVSim, HeteroGenesis) assessing their ability to control biological parameters , including variants characteristics (type, number, position, length, content, zygosity), and sample characteristics (clonality, contamination); and technical parameters , including reads characteristics (sequencing errors, coverage, base qualities). No single simulator provided complete control over both biological and technical parameters, nor guidance on tuning biological parameters for cancer-specific simulations. Consequently, we developed MOV&RSim, a novel simulator that leverages data-driven information to set variants and reads characteristics, producing realistic tumoral samples, and providing full control on biological and technical parameters. Additionally, we leveraged well-annotated variant databases to create cancer-specific presets that inform the simulator’s parameters for 21 cancer types. Conclusion: This new simulator, containerised with Docker and freely available for academic use, empowers users to define each biological parameter of a tumoral genome and faithfully replicates the variability of technical noise observed in real sequencing reads. The proposed simulator and presets represent the most adaptable and comprehensive framework currently available for generating tumor samples, enabling comprehensive benchmarking and, ultimately, the optimization of somatic variant callers across diverse cancer types.
- Open Access
- 6 October 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-12
Uncover a microbiota signature of upper respiratory tract in patients with SARS-CoV-2 +
The outbreak of Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, forced us to face a pandemic with unprecedented social, economic, and public health consequences. Several nations have launched campaigns to immunize millions of people using various vaccines to prevent infections. Meanwhile, therapeutic approaches and discoveries continuously arise; however, identifying infected patients that are going to experience the more severe outcomes of COVID-19 is still a major need, to focus therapeutic efforts, reducing hospitalization and mitigating drug adverse effects. Microbial communities colonizing the respiratory tract exert significant effects on host immune responses, influencing the susceptibility to infectious agents. Through 16S rDNAseq we characterized the upper airways’ microbiota of 192 subjects with nasopharyngeal swab positive for SARS-CoV-2. Patients were divided into groups based on the presence of symptoms, pneumonia severity, and need for oxygen therapy or intubation. Indeed, unlike most of the literature, our study focuses on identifying microbial signatures predictive of disease progression rather than on the probability of infection itself, for which a consensus is lacking. Diversity, differential abundance, and network analysis at different taxonomic levels were synergistically adopted, in a robust bioinformatic pipeline, highlighting novel possible taxa correlated with patients’ disease progression to intubation.
- 6 October 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-12
Open AccessUncover a microbiota signature of upper respiratory tract in patients with SARS-CoV-2 +
The outbreak of Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, forced us to face a pandemic with unprecedented social, economic, and public health consequences. Several nations have launched campaigns to immunize millions of people using various vaccines to prevent infections. Meanwhile, therapeutic approaches and discoveries continuously arise; however, identifying infected patients that are going to experience the more severe outcomes of COVID-19 is still a major need, to focus therapeutic efforts, reducing hospitalization and mitigating drug adverse effects. Microbial communities colonizing the respiratory tract exert significant effects on host immune responses, influencing the susceptibility to infectious agents. Through 16S rDNAseq we characterized the upper airways’ microbiota of 192 subjects with nasopharyngeal swab positive for SARS-CoV-2. Patients were divided into groups based on the presence of symptoms, pneumonia severity, and need for oxygen therapy or intubation. Indeed, unlike most of the literature, our study focuses on identifying microbial signatures predictive of disease progression rather than on the probability of infection itself, for which a consensus is lacking. Diversity, differential abundance, and network analysis at different taxonomic levels were synergistically adopted, in a robust bioinformatic pipeline, highlighting novel possible taxa correlated with patients’ disease progression to intubation.
- 11 September 2023
- Published by Springer Nature
- p. 85-96
DAVI: A Dataset for Automatic Variant Interpretation
- 11 September 2023
- Published by Springer Nature
- p. 85-96
DAVI: A Dataset for Automatic Variant Interpretation